Pretarget carcinoma therapy
Alternative Names: Pretarget pancreatic/colorectal therapyLatest Information Update: 07 Apr 2004
At a glance
- Originator Poniard Pharmaceuticals
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer; Gastrointestinal cancer; Pancreatic cancer
Most Recent Events
- 07 Apr 2004 NeoRx's Pretarget® technology has been licensed to Aletheon Pharmaceuticals worldwide
- 04 Jul 2003 NeoRx's Pretarget® technology is available for licensing (http://www.neorx.com)
- 04 Jul 2003 Data presented at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO-2003)have been added to the pharmacokinetics section